A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers

The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.

This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and irinotecan.

Inclusion Criteria:

• No standard options remaining
• Adequate liver and kidney functions
• 18 years of age or above

Exclusion Criteria:

• History of any secondary active cancer in the last 3 years.
• Pregnant or breast feeding
• History of severe allergic reactions or contraindications to cetuximab or irinotecan